Skip to main content
SpringerLink
Log in

Nivolumab may be too costly for lung cancer in Netherlands

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • van Eijsden P. Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly. BMJ 2015: h6778, No. 351, 15 Dec 2015. Available from: URL: http://dx.doi.org/10.1136/bmj.h6778

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nivolumab may be too costly for lung cancer in Netherlands. PharmacoEcon Outcomes News 743, 8 (2015). https://doi.org/10.1007/s40274-015-2673-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2673-x

Search

Navigation